ActiQs
Mer att utforska

Verktyg för dig

Kombinationer Mina bevakningar

För professionella

Ämnesregister Källregister API & data
ActiQs / Forskning
PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för momelotinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

45 träffar
Bibliografisk träff 2024-03-19

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R.

Leuk Lymphoma · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1080/10428194.2024.2328800
Bibliografisk träff 2024-02-02

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.

Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan D, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AA, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Mesa RA.

Value Health · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jval.2024.01.014
Bibliografisk träff 2023-07-27

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.

Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R.

Lancet Haematol · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s2352-3026(23)00174-6
Bibliografisk träff 2023-04-06

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.

Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S.

Cancer Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.5799
Bibliografisk träff 2023-01-01

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R, MOMENTUM Study Investigators.

Lancet · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(22)02036-0
Bibliografisk träff 2022-07-22

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.

Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S.

Leukemia · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1038/s41375-022-01637-7
Bibliografisk träff 2022-03-07

Momelotinib reduces transfusion requirements in patients with myelofibrosis.

Mesa R, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Palmer J, Platzbecker U, Treliński J, Shimoda K, Donahue R, D'Hollander K, Kowalski M, Verstovsek S.

Leuk Lymphoma · letter; research support, non-u.s. gov't · DOI 10.1080/10428194.2022.2043304
Bibliografisk träff 2022-02-01

Momelotinib is a highly potent inhibitor of FLT3-mutant AML.

Azhar M, Kincaid Z, Kesarwani M, Ahmed A, Wunderlich M, Latif T, Starczynowski D, Azam M.

Blood Adv · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/bloodadvances.2021004611
Bibliografisk träff 2018-07-30

Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS.

Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-018-0650-5
Bibliografisk träff 2018-03-07

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Cancer J · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1038/s41408-018-0067-6